Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Opdualag 240 mg/80 mg concentrate for solution for infusion {equilateral_black_triangle}

Active Ingredient:
nivolumab , relatlimab
Company:  
Bristol Myers Squibb Pharmaceuticals limited See contact details
ATC code: 
L01FY02
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Letters to HCPs HCP Med Info
{arrow_left}
{arrow_right}

Important information for Healthcare Professionals

{pdf_link}

UK Opdualag (nivolumab and relatlimab fixed dose combination) Healthcare Professional Letter – Introduction of an Additional Risk Minimisation Material

{healthcare_pro_orange} For Healthcare Professionals
This letter contains important safety information regarding the introduction of a Patient Card as part of the marketing authorisation for Opdualag (nivolumab and relatlimab fixed dose combination).

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Bristol Myers Squibb Pharmaceuticals limited
Company image
Address
Bristol-Myers Squibb, ARC Uxbridge, Sanderson Road, New Denham, Denham, Buckinghamshire, UB8 1DH, UK
Telephone
+44 (0)1895 523 000
Medical Information e-mail
[email protected]
Medical Information Direct Line
+44 (0) 800 731 1736
Medical Information Website
https://www.bmsmedinfo.co.uk/